Briefly, by conducting experiments at the cellular, tissue, and animal levels, the researchers verified that targeting the IFN-AHR signaling pathway may be a potential strategy for effective treatment of patients with COVID-19 and provided a new therapeutic idea for dyspnea caused by SARS-CoV-2 infection. The gene discussed is AHR; the disease is COVID-19.